Akston Launches Clinical Trial for Novel Canine Cancer Therapy
Akston Biosciences Corporation has partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors.
The clinical study will evaluate a first-in-class immuno-enhancing therapy supported by the proprietary Fc-fusion protein platform Ambifect.
- The intramuscular injection therapy targets PD-L1 in dogs with solid tumors.
- The study was launched in partnership with Purdue University's College of Veterinary Medicine.
The first patient in the study is Rocco, an 11-year-old Dutch shepherd dog diagnosed with high-grade soft tissue sarcoma.
Rocco recently received the first dose of the trial therapy after his tumor returned following surgery.
Akston Biosciences Corporation is leading the study in West Lafayette, Indiana.
Author's summary: Akston launches clinical trial for canine cancer therapy.
More News
- Editorial: Movable bike barrier a good step for Richmond Bridge
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks
- Inquiring Photographer: Thoughts on Reduced Speed Limit for E-bikes and E-Scooters of 15 mph - Norwood News
- An Illinois wealth tax would be a legal disaster
- 20 Cool Orlando Museums You Didn’t Know Existed (No Theme Parks Required!)
- 12 A-List Actors Who Got Their Start in Horror Movies